NASDAQ:DNLI

Denali Therapeutics Inc Earning Date

USA |NASDAQ |USD

DNLI Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 3, 2021 Sep 2021 $-0.47 $-0.50 $-0.54
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 3, 2021 Sep 2021 $30.28M $22.94M $9.39M

Denali Therapeutics Inc's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.

DNLI Earnings Date & History Chart

DNLI Earnings & Revenue Forecast

DNLI Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 13 $-0.38 $-0.66 $0.19
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 14 $-1.96 $-2.38 $-1.28
Dec 2022 14 $-2.27 $-3.73 $-1.39

DNLI Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.38 $-0.38 $-0.40
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-1.96 $-1.88 $-1.82
Dec 2022 1 / 0 $-2.27 $-2.16 $-2.15

DNLI Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 11 $44.04M $4.00M $92.66M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 14 $93.59M $38.86M $177.11M
Dec 2022 14 $99.68M $30.00M $200.00M

DNLI Earnings Date & Revenue History

DNLI Earnings History

|
Show More
Show More

DNLI Revenue History

|
Show More
Show More

Denali Therapeutics Inc Next Earnings Date & Report

DNLI Next Earnings Date & Report Preview: Sep 2021 (FQ)

DNLI's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 13 analysts, the average EPS estimation for Denali Therapeutics Inc's next quarterly earnings is $-0.47, with a low EPS estimation of $-0.66, and a high estimation of $-0.10.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.47, the last 2 month trend is $-0.47, and the 3 month trend is $-0.46.

Based on 10 analysts, the average revenue estimation is $30.28M, with a low revenue estimation of $4.00M, and a high estimation of $70.00M.

Denali Therapeutics Inc Previous Earnings Dates & Reports

DNLI Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Denali Therapeutics Inc's previous earnings date was Aug 4, 2021 for its fiscal quarter ended Jun 30, 2021.

DNLI's earnings per share (EPS) was $-0.50, missing the consensus analysts forecast of $-0.36 by -38.73%.

The EPS was higher than the previous fiscal quarter (Mar 2021) by -13.79%, and higher than the same period a year before (Jun 2020) by -10.71%.

Revenues were $22.94M, better than the forecast of $22.94M by 0.00%, up by 189.52% from the previous quarter , and up by 292.32% from the same period last year.

The company reported a net income of $-60.69M.

Free cash flow for the quarter was $-54.99M , compared to $-53.04M last quarter and $-43.67M a year before.

DNLI ended the quarter with $66.45M in total debt, a decrease of -1.98% compared to the previous quarter, and a decrease of -6.33% compared to the same quarter a year before.

DNLI Previous Earnings Date & Report Recap: Dec 2020 (FY)

Denali Therapeutics Inc's previous annual earnings date was Feb 25, 2021 for its fiscal year ended Dec 31, 2020.

DNLI's earnings per share (EPS) was $0.26, beating the consensus analysts forecast of $-1.57 by -116.56% , and higher than the previous year's EPS (Dec 2019) by -112.62%.

Revenues were $335.66M.

The company reported a net income of $71.14M.

Denali Therapeutics Inc reported a free cash flow of $413.06M for its fiscal year, compared to $-169.50M a year ago.

The company ended the fiscal year with $68.86M in total debt, a decrease of -5.05% compared to the previous year.